Erythroderma Suspected Caused by Sambiloto (Andrographis paniculata): A Case Report
DOI:
https://doi.org/10.37287/ijghr.v7i6.172Keywords:
adverse drug reaction, erythroderma, herbal medicine, sambilotoAbstract
Erythroderma, or Exfoliative Dermatitis (ED), is a serious dermatological emergency marked by erythema and scaling over more than 90% of the body surface area. Although etiologies are diverse, drug reactions remain a major cause. Beyond conventional pharmaceuticals such as antibiotics, antivirals, anti-inflammatory agents, cardiac drugs, and chemotherapeutics, herbal remedies have also been linked to hypersensitivity reactions. Sambiloto (Andrographis paniculata), a traditional antidiabetic widely used in Southeast Asia, has been reported to trigger severe cutaneous adverse reactions, including erythroderma. We present the case of a 53-year-old woman with diabetes mellitus who developed generalized erythematous macules, scaling, severe pruritus, fever, chills, and fatigue four days after consuming a Sambiloto decoction. She denied the use of other medications. Clinical findings supported by histopathological analysis confirmed erythroderma. Management involved discontinuation of the suspected herbal, systemic corticosteroids, antihistamines, moisturizers, antibiotics, and glucose control, leading to marked improvement within eight days. This case highlights that drug-induced erythroderma often has an acute onset and rapid course. Despite their reputation for safety, herbal medicines may provoke severe hypersensitivity reactions with potentially life-threatening outcomes. Comprehensive drug history-taking, including traditional remedies, is therefore essential in evaluating patients with exfoliative dermatitis. The objective of this report and journal is to raise awareness of herbal-induced erythroderma and to contribute to the growing body of evidence regarding the risks of traditional therapies. Early recognition and prompt withdrawal of the causative agent remain critical for preventing recurrence and improving patient outcomes.
References
Tso, S., Satchwell, F., Moiz, H., et al. (2021). Erythroderma (exfoliative dermatitis). Part 1: Underlying causes, clinical presentation and pathogenesis. Clinical and Experimental Dermatology, 46(6), 1001–1010. https://doi.org/10.1111/ced.14625
Grant-Kels, J. M., Fedeles, F., & Rothe, M. J. (2012). Exfoliative dermatitis. In L. A. Goldsmith, S. I. Katz, B. A. Gilchrist, A. S. Paller, D. J. Leffel, & K. Wolff (Eds.), Fitzpatrick’s dermatology in general medicine (8th ed., Vol. 2). McGraw-Hill.
Shang, Y. X., Shen, C., Stub, T., et al. (2022). Adverse effects of andrographolide derivative medications compared to the safe use of herbal preparations of Andrographis paniculata: Results of a systematic review and meta-analysis of clinical studies. Frontiers in Pharmacology, 13, 773282. https://doi.org/10.3389/fphar.2022.773282
Suwankesawong, W., Saokaew, S., Permsuwan, U., & Chaiyakunapruk, N. (2014). Characterization of hypersensitivity reactions reported among Andrographis paniculata users in Thailand using Health Product Vigilance Center (HPVC) database. BMC Complementary and Alternative Medicine, 14, 515. https://doi.org/10.1186/1472-6882-14-515
Hoxha S., Fida M., R., Malaj R., Vasili E. EMJ Allergy & Immunology. (2020, April 6). Erythroderma: A manifestation of cutaneous and systemic diseases. EMJ Allergy & Immunology. https://doi.org/10.33590/emjallergyimmunol/19-00182
Austad, S., & Athalye, L. (2022). Exfoliative dermatitis. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554568/
Albalawi, H., Altemani, A., Alhweiti, A., et al. (2024). Diagnosis and management of erythroderma: A systematic review. International Journal of Medicine in Developing Countries, 387–395. https://doi.org/10.24911/IJMDC.51-1700391422
Inamadar, A. C., & Ragunatha, S. (2019). The rash that becomes an erythroderma. Clinics in Dermatology, 37(2), 88–98. https://doi.org/10.1016/j.clindermatol.2018.12.002
World Health Organization. (2019). WHO global report on traditional and complementary medicine 2019. World Health Organization. https://apps.who.int/iris/handle/10665/312342
Hartini, Y. S., Setyaningsih, D., Chang, M. J. V., & Nugrahanti, M. C. I. A. (2021). Sambiloto (Andrographis paniculata Nees.) leaf extract activity as an α-amylase enzyme inhibitor. Pharmacy Education, 21(2), 305–308. https://doi.org/10.46542/pe.2021.212.305308
Zeng, B., Wei, A., Zhou, Q., et al. (2022). Andrographolide: A review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches. Phytotherapy Research, 36(1), 336–364. https://doi.org/10.1002/ptr.732
Hayati, L., & Hidayat, R. (2020). The effects of Sambiloto leaf extract (Andrographis paniculata) on blood sugar regulation: An in vivo study. Eureka Herba Indonesia, 1(1), 1–8. https://doi.org/10.37275/ehi.v1i1.1
Therapeutic Goods Administration. (2024, January 6). Medicines containing Andrographis paniculata safety advisory. Australian Government Department of Health and Aged Care. https://www.tga.gov.au/news/safety-alerts/medicines-containing-andrographis-paniculata-safety-advisory
Heelan, K., Sibbald, C., & Shear, N. H. (2019). Cutaneous reaction to drugs. In S. Kang, M. Amagai, A. L. Bruckner, A. H. Enk, D. J. Margolis, A. J. McMichael, & et al. (Eds.), Fitzpatrick’s dermatology (9th ed., pp. 749–764). McGraw-Hill.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Indonesian Journal of Global Health Research

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.








